表紙
市場調查報告書

腎障礙生物標記的全球市場

Renal Biomarkers Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 567962
出版日期 內容資訊 英文 119 Pages
商品交期: 2-3個工作天內
價格
Back to Top
腎障礙生物標記的全球市場 Renal Biomarkers Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 119 Pages
簡介

本報告提供腎障礙生物標記的全球市場調查,市場概要,各生物標記類型、診斷技術、終端用戶、地區的市場趨勢,市場的促進、阻礙因素及課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 簡介

  • 市場定義

第2章 調查手法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 波特的五力分析

第6章 市場動態

  • 推動因素
  • 阻礙因素
  • 市場機會
  • 市場課題

第7章 市場區隔:各生物標記類型

  • 腎功能檢驗生物標記
    • 血清血肌酐
    • 血清胱抑素 C
    • 尿中白蛋白
  • 正調節的蛋白質生物標記
    • 嗜中性白血球明膠相關性脂質運載蛋白(NGAL)
    • 尿中腎障礙分子(Kim-1)
    • 白細胞介素-18
  • 其他生物標記

第8章 市場區隔:各診斷技術

  • ELISA
  • PETIA
  • 比色分析法
  • CLIA
  • 液體層析法/質譜分析(LC/MS)

第9章 市場區隔:各終端用戶

  • 診斷實驗室
  • 門診病人診療所
  • 調查中心
  • 醫院

第10章 市場區隔:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 西班牙
    • 義大利
    • 法國
    • 德國
    • 其他
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第11章 競爭情形

  • 收購、合併
  • 聯盟、合作、協定
  • 新產品的投入

第12章 企業簡介

  • Beckman Coulter, Inc.
  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • BIOPORTO A/S
  • Astute Medical, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthcare Diagnostics, Inc.
  • Alere, Inc.
  • F. Hoffmann-La Roche AG
  • BioMerieux SA

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54468

Market Overview

The global renal biomarkers market was valued at USD 1,023.04 million in 2018, and is estimated to be valued at USD 1,552.60 million in 2024, witnessing a CAGR of 7.20%. The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics.

Advancements in the field of genetic technology during the last decade have enlightened people's knowledge regarding genetic regulatory pathways related to renal biomarkers. Due to rapid advances in genomic technologies, genetics analyses have become essential in clinical practice and research. Moreover, with the development of computer technology, renal biomarkers testing has become widely accessible and feasible to perform, even in small-sized laboratories. Recent advances in genetics have created opportunities to study kidney disease in a variety of platforms, applied to human populations. Renal biomarkers can also be integrated into genetic-level technological advancements for the detection, diagnosis, and treatment of kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drives the market.

Scope of the Report

In the report, a detailed analysis of the global renal biomarkers market is provided. The market is evaluated by collating revenues generated across segments, categorized by biomarker type, diagnostic technique, and end user.

Key Market Trends

Functional Biomarker is Expected to hold its Highest Market Share in the Biomarker Type Segment

In the biomarker type segment of the market, the functional biomarker is believed to have the largest market size and is expected to witness a CAGR of 6.94% during the forecast period.

Chronic kidney disease (CKD) has become a public health problem. According to the National Institute of Diabetes, Digestives and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made usually on the levels of serum creatinine (SCr). The serum creatinine, a functional biomarker, dominates the market of renal biomarkers, owing to the high prevalence rate of CKD and high presence and knowledge of serum creatinine biomarker.

North America Dominates the Market and Expected to do the Same in the Forecast Period

North America currently dominates the market for renal biomarkers and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.

Competitive Landscape

The renal biomarkers market is highly competitive and consists of several major players, along with multiple smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Thermofisher Scientific, Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche, and BioMerieux, hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Various Kidney-related Diseases
    • 4.2.2 The High Prevalence of Diabetes and High Blood Pressure, the Leading Cause of Renal Diseases
    • 4.2.3 Rapid Technological Advances In The Field Of Genetics
  • 4.3 Market Restraints
    • 4.3.1 Issues Related to Regulatory and Reimbursement Systems
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Biomarker Type
    • 5.1.1 Functional Biomarker
      • 5.1.1.1 Serum Creatinine
      • 5.1.1.2 Serum Cystatin C
      • 5.1.1.3 Urine Albumin
    • 5.1.2 Up-regulated Protein
      • 5.1.2.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
      • 5.1.2.2 Kidney Injury Molecule-1
      • 5.1.2.3 INTERLEUKIN-18
  • 5.2 Diagnostic Technique
    • 5.2.1 Enzyme-linked Immunosorbent Assay
    • 5.2.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
    • 5.2.3 Colorimetric Assay
    • 5.2.4 Chemiluminescent Enzyme Immunoassay (CLIA)
    • 5.2.5 Liquid Chromatography Mass Spectrometry (LS-MS)
  • 5.3 End User
    • 5.3.1 Hospital
    • 5.3.2 Diagnostic Laboratory
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Beckman Coulter Inc. (Danaher Corporation)
    • 6.1.2 Thermo Fisher Scientific Inc.
    • 6.1.3 Abbott Molecular Inc. (Abbott Laboratories Ltd)
    • 6.1.4 Bioporto AS
    • 6.1.5 Astute Medical Inc.
    • 6.1.6 Randox Laborotories Ltd
    • 6.1.7 Siemens Healthcare
    • 6.1.8 Cobo Scientific Biomedical Research
    • 6.1.9 F. Hoffmann-La Roche Ag
    • 6.1.10 Biomerieux

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top